7th PAGE Meeting

Wuppertal - Germany
19-20 June, 1998

View abstracts

Home / 1998 – Wuppertal – Germany / Abstracts

← Back to filters

Abstracts (18)

ML McFadyen(1), SF Marshall (2), PA Milligan(2), DJ Nichols(2) MO Karlsson(3)

Clinical versus statistical significance in covariate selection

Misba Beerahee, PhD(1) and Mark Sale, MD(2)

An integrated population PK-PD model characterising the time course of exposure and clinical endpoints (biochemical, physiological and haemodynamics) for 546C88, a nitric oxide synthase inhibitor, in patients with septic shock.

J.-L. Steimer, B. Fotteler, R. Gieschke, H.Wiltshire, N. Buss

Mixed-effects modeling and simulation of the Dose-AUC relationship of saquinavir in healthy subjects and HIV-positive patients (II)

Silvy Laporte, Pascal Girard, Patrick Mismetti, Sylvie Chabaud

What Is The Relevance Of Estimating Inter-Study Variability In Population Pharmacokinetic Meta-Analysis?

Mats O Karlsson and E Niclas Jonsson

An Automated Stepwise Covariate Model Building Procedure Within NONMEM

Dave Lunn and Jon Wakefield

The analysis of ordinal pharmacodynamic data: applicationto allergy score.

SB Duffull (1), JJ Deely (2). NHG Holford (3).

Comparison Of A Semiparametric Method With Nonmem For Population Analysis Of Simulated Data

Kazimierz H. Kozlowski

Semi-Populational Model For Analysis Of Infusable Immunoglobulin-G Pharmacokinetics In VLBW Infants

S. F. Marshall(1), P. A. Milligan(1), D. J. Nichols(1) and M. O. Karlsson(2)

Do we require the population approach to dose adjust in renal impairment? : A case study with dofetilide

Davide Verotta

Mechanistic and Non-mechanistic Drug Dynamics Modeling

Rashmi R Shah

Limitations of Population Approaches in Regulatory Assessment of New Chemical Entities

Jean-Michel Gries, Pharm.D, Ph.D.(1), Davide Verotta, Ph.D.(2), Lewis B. Sheiner, M.D.(3)

Estimation of individual pharmacokinetic parameters in presence of possible non-compliance

Nick Holford

Clinical Pharmacology = Disease Progress + Drug Action. The role of clinical trial modelling, simulation and analysis using the population PKPD approach.

Silvy Laporte, Pascal Girard, Patrick Mismetti, Sylvie Chabaud

What Is The Relevance Of Estimating Inter-Study Variability In Population Pharmacokinetic Meta-Analysis ?

Rik C. Schoemaker, Joop M.A. van Gerven & Adam F. Cohen

Estimating potency for the Emax-model without attaining maximal effects

Gordon Graham1, Leon Aarons1 and Suneel Gupta2

A Bayesian Analysis of Categorical and Count Pharmacodynamic Data

Roberto Gomeni1, Jean M. Joulia1,2, Frédéric Pinguet 2, Marc Ychou3 and Françoise Bressolle1,2

Circadian Population Pharmacokinetics of 5-Fluorouracil (5-FU) in Patients with Metastatic Colorectal Cancer

Janet Wade

Miscellaneous regulatory information